RESUMO
This case report illustrates how to implant a central paracorporeal temporary biventricular assist device in a 17-year-old patient with acute heart failure due to a fulminant form of coronavirus disease 2019 myocarditis. The procedure was carried out after prior veno-arterial extracorporeal membrane oxygenation support. Myocardial biopsies and biventricular assist device explants are also included in the report. The patient was weaned on postoperative day 6 and discharged without any significant complications. One year after the event, the patient remains asymptomatic with normal biventricular function and a normal lifestyle.
Assuntos
COVID-19 , Insuficiência Cardíaca , Coração Auxiliar , Miocardite , Humanos , Miocardite/cirurgia , COVID-19/complicações , Adolescente , Insuficiência Cardíaca/cirurgia , Masculino , SARS-CoV-2 , Oxigenação por Membrana Extracorpórea/métodos , Remoção de Dispositivo/métodosRESUMO
OBJECTIVES: Myocardial recovery in children supported by a durable left ventricular assist device is a rare, but highly desirable outcome because it could potentially eliminate the need for a cardiac transplant and the lifelong need for immunosuppressant therapy and the risk of complications. However, experience with this specific outcome is extremely limited. METHODS: All patients < 19 years old supported by a durable left ventricular assist device from the European Registry for Patients with Mechanical Circulatory Support database were included. Participating centres were approached for additional follow-up data after explantation. Associated factors for explantation due to myocardial recovery were explored using Cox proportional hazard models. RESULTS: The incidence of recovery in children supported by a durable left ventricular assist device was 11.7% (52/445; median duration of support, 122.0 days). Multivariable analyses showed body surface area (hazard ratio 0.229; confidence interval 0.093-0.565; P = 0.001) and a primary diagnosis of myocarditis (hazard ratio 4.597; confidence interval 2.545-8.303; P < 0.001) to be associated with recovery. Left ventricular end-diastolic diameter in children with myocarditis was not associated with recovery. Follow-up after recovery was obtained for 46 patients (88.5%). Sustained myocardial recovery was reported in 33/46 (71.7%) at the end of the follow-up period (28/33; >2 year). Transplants were performed in 6/46 (11.4%) (in 5 after a ventricular assist device was reimplanted). Death occurred in 7/46 (15.2%). CONCLUSIONS: Myocardial recovery occurs in a substantial portion of paediatric patients supported with durable left ventricular assist devices, and sustainable recovery is seen in around three-quarters of them. Even children with severely dilated ventricles due to myocarditis can show recovery. Clinicians should be attentive to (developing) myocardial recovery. These results can be used to develop internationally approved paediatric weaning guidelines.
Assuntos
Insuficiência Cardíaca , Transplante de Coração , Coração Auxiliar , Miocardite , Humanos , Criança , Adulto Jovem , Adulto , Coração Auxiliar/efeitos adversos , Miocardite/cirurgia , Miocárdio , Diástole , Insuficiência Cardíaca/cirurgia , Resultado do TratamentoRESUMO
Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All patients were hospitalized in the intensive care unit and 92.7% (n = 102) were on life support prior to transplantation. No patients with COVID-19 myocarditis required ventilation while waitlisted. Survival free from graft failure was 100% among COVID-19 patients and 88.5% among non-COVID-19 patients at a median of 257 (range 0-427) days post-transplant. These findings indicate that transplantation is rarely performed for COVID-19 related cardiomyopathy in the United States, yet early outcomes appear favorable in select patients.
Assuntos
COVID-19 , Cardiomiopatias , Transplante de Coração , Adulto , Idoso , Humanos , Pessoa de Meia-Idade , Adulto Jovem , Cardiomiopatias/epidemiologia , Cardiomiopatias/etiologia , Cardiomiopatias/cirurgia , COVID-19/complicações , COVID-19/epidemiologia , Transplante de Coração/efeitos adversos , Transplante de Coração/estatística & dados numéricos , Doenças Musculares/complicações , Miocardite/etiologia , Miocardite/cirurgia , Resultado do Tratamento , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: There is limited and conflicting information on waitlist and transplant outcomes for children with myocarditis. METHODS: Retrospective review included children with myocarditis and dilated cardiomyopathy (DCM) listed for HT from January 01, 1993 to December 31, 2019 in the Pediatric Heart Transplant Society database. Clinical characteristics, waitlist and post-HT outcomes (graft loss, rejection, cardiac allograft vasculopathy, infection and malignancy) for children listed from early (1993-2008) and current era (2009-2019) with myocarditis were evaluated and compared to those with DCM. RESULTS: Of 9755 children listed, 322 (3.3%) had myocarditis and 3178 (32.6%) DCM. Compared to DCM, children with myocarditis in the early and the current era were significantly more likely to be listed at higher urgency; be in intensive care unit; on mechanical ventilation; extracorporeal membrane oxygenation and ventricular assist device (p < 0.05 for all). While unadjusted analysis revealed lower transplant rates and higher waitlist mortality for children with myocarditis, in multivariable analysis, myocarditis was not a risk factor for waitlist mortality. Myocarditis, however, was a significant risk factor for early phase post-HT graft loss (HR 2.46; p = 0.003). Waitlist and post-HT survival for children with myocarditis were similar for those listed and transplanted in the early era to those listed and transplanted in the current era (p > 0.05 for both). CONCLUSIONS: Children with myocarditis have a higher acuity of illness at listing and at HT and have inferior post-HT survival compared to children with DCM. Outcomes for children with myocarditis have not improved over the 3 decades and efforts are needed to improve outcomes for this cohort.
Assuntos
Cardiomiopatia Dilatada , Transplante de Coração , Miocardite , Criança , Humanos , Miocardite/cirurgia , Fatores de Risco , Estudos Retrospectivos , Listas de EsperaRESUMO
Granulomatous myocarditis is an inflammatory disease of the myocardium, characterized by lymphocytic infiltration with characteristic granuloma formation. Although a host of disease processes can elicit myocardial granulomas, two common entities are cardiac sarcoidosis and cardiac tuberculosis. Cardiac arrhythmias in this condition are frequent and management of ventricular arrhythmias can be challenging, especially in those with drug-refractory ventricular tachycardia and electrical storm. In this review, we highlight the role of catheter ablation for ventricular tachycardia and optimal patient selection for catheter ablation, based on cardiac imaging.
Assuntos
Ablação por Cateter , Miocardite , Taquicardia Ventricular , Humanos , Miocardite/complicações , Miocardite/cirurgia , Resultado do Tratamento , Taquicardia Ventricular/cirurgia , Ablação por Cateter/métodos , Arritmias Cardíacas/cirurgiaRESUMO
Giant cell myocarditis (GCM) is one of the rare diseases that cause fatal heart failure and suspected to be associated with autoimmune disorder. There are few reports that the patients of GCM live long because of their progressive heart failure. We report a rare case of patient who was suspected two long hospitalizations due to heart failure in her childhood and peripartum period, and incidentally diagnosed with GCM by myocardial biopsy performed at the aortic valve replacement and mitral annuloplasty for severe aortic valve regurgitation and moderate mitral regurgitation.
Assuntos
Insuficiência Cardíaca , Anuloplastia da Valva Mitral , Insuficiência da Valva Mitral , Miocardite , Criança , Feminino , Células Gigantes/patologia , Insuficiência Cardíaca/complicações , Humanos , Insuficiência da Valva Mitral/diagnóstico por imagem , Insuficiência da Valva Mitral/etiologia , Insuficiência da Valva Mitral/cirurgia , Miocardite/complicações , Miocardite/diagnóstico , Miocardite/cirurgiaRESUMO
BACKGROUND: Fulminant myocarditis (FM) is a form of severe inflammatory carditis with rapidly developing acute heart failure. CASE PRESENTATION: We report three cases of successful intensive treatment by Impella of FM without any complications. In all cases, impairment of microcirculation as measured by blood lactate level and the hemodynamic value as indicated by cardiac index were improved within 24-48 h and 7 days after Impella implantation, respectively. Interestingly, our data also suggested that treatment by Impella CP or 5.0 may lead to faster recovery of microcirculation and cardiac function than treatment by Impella 2.5. CONCLUSION: Our findings demonstrate that the appropriate selection of Impella devices guided by body surface area measurements may help to improve clinical outcomes of severe heart failure including FM.
Assuntos
Insuficiência Cardíaca , Coração Auxiliar , Miocardite , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/cirurgia , Coração Auxiliar/efeitos adversos , Hemodinâmica , Humanos , Miocardite/cirurgia , Choque Cardiogênico/etiologia , Resultado do TratamentoRESUMO
Ventricular aneurysm after myocarditis is a rare complication. It has been reported that scarred areas of the myocardium may become aneurysm. Here, we report a case of apical left ventricle aneurysm at 18 years after the fulminant myocarditis. The patient is a 36-year-old female with a history of fulminant myocarditis at the age of 18. Eighteen years after the onset of the disease, she was referred to our hospital because of an apex ventricular aneurysm. Her computed tomography scan showed an apex ventricular aneurysm sized 45×40 mm with a wall width of 1.8 mm. We performed resection of ventricular aneurysm and reconstruction using Linear technique. The postoperative course was uneventful and discharged on the 17th post operative day.
Assuntos
Aneurisma Cardíaco , Miocardite , Adulto , Feminino , Aneurisma Cardíaco/diagnóstico por imagem , Aneurisma Cardíaco/cirurgia , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/cirurgia , Humanos , Miocardite/complicações , Miocardite/diagnóstico por imagem , Miocardite/cirurgia , Tomografia Computadorizada por Raios XAssuntos
Células Gigantes/patologia , Infecções por HIV/complicações , Neoplasias Cardíacas/complicações , Transplante de Coração/métodos , Miocardite/cirurgia , Miocárdio/patologia , Sarcoma de Kaposi/complicações , Adulto , HIV , Neoplasias Cardíacas/diagnóstico , Humanos , Masculino , Miocardite/complicações , Miocardite/diagnóstico , RecidivaRESUMO
BACKGROUND: Little is known about the risk stratification of patients with myocarditis undergoing ventricular tachycardia (VT) ablation. OBJECTIVES: This study sought to describe VT ablation results and identify factors associated with arrhythmia recurrences in a cohort of patients with myocarditis. METHODS: The authors enrolled 125 consecutive patients with myocarditis, undergoing VT ablation. Before ablation, disease stage was evaluated, to identify active (AM) versus previous myocarditis (PM). The primary study endpoint was assessment of VT recurrences by 12-month follow-up. Predictors of VT recurrences were retrospectively identified. RESULTS: All patients (age 51 ± 14 years, 91% men, left ventricular ejection fraction 52% ± 9%) had history of myocarditis diagnosed by endomyocardial biopsy (59%) and/or cardiac magnetic resonance (90%). Furthermore, all had multiple episodes of drug-refractory VTs. Multimodal pre-procedural staging identified 47 patients with AM (38%) and 78 patients with PM (62%). All patients showed low-voltage areas (LVA) at electroanatomical map (97% epicardial or endoepicardial); of them, 25 (20%) had wide borderzone (WBZ, constituting >50% of the whole LVA). VT recurrences were documented in 25 patients (20%) by 12 months, and in 43 (34%) by last follow-up (median 63 months; interquartile range: 39 to 87). At multivariable analysis, AM stage was the only predictor of VT recurrences by 12 months (hazard ratio: 9.5; 95% confidence interval: 2.6 to 35.3; p < 0.001), whereas both AM stage and WBZ were associated with arrhythmia recurrences anytime during follow-up. No VT episodes were found after redo ablation was performed in 23 patients during PM stage. CONCLUSION: Our findings suggest that VT ablation should be avoided during AM, but is often of benefit for recurrent VT after the acute phase of myocarditis.
Assuntos
Ablação por Cateter/tendências , Miocardite/diagnóstico por imagem , Miocardite/metabolismo , Taquicardia Ventricular/diagnóstico por imagem , Taquicardia Ventricular/metabolismo , Adulto , Idoso , Ablação por Cateter/efeitos adversos , Estudos de Coortes , Feminino , Humanos , Inflamação/diagnóstico por imagem , Inflamação/etiologia , Inflamação/metabolismo , Masculino , Pessoa de Meia-Idade , Miocardite/cirurgia , Tomografia por Emissão de Pósitrons/métodos , Valor Preditivo dos Testes , Recidiva , Estudos Retrospectivos , Taquicardia Ventricular/etiologiaRESUMO
We report a rare case of liver alveolar echinococcosis with an invasion of the hepaticocaval confluence, inferior vena cava, pericardium, right atrium, atrial septum, and superior vena cava, and its successful treatment by combined heart-liver transplantation.
Assuntos
Equinococose Hepática/cirurgia , Equinococose/cirurgia , Transplante de Coração/métodos , Transplante de Fígado/métodos , Miocardite/parasitologia , Miocardite/cirurgia , Adulto , Feminino , Átrios do Coração , Septos Cardíacos , Humanos , Pericárdio , Resultado do Tratamento , Veia Cava Inferior , Veia Cava SuperiorRESUMO
Persistent infection of left ventricular-assisted devices are challenging to treat. We describe a case of a middle-aged man who presented with cardiogenic shock and profound heart failure from sarcoid myocarditis, necessitating the placement of a left ventricular assist device. After recovery of cardiac function, the device was decommissioned but complicated by infection in the implant bed, chest wall, and of the titanium plug left in situ. This to our knowledge is the first report of an infected titanium plug and we describe an option of using a latissimus dorsi flap using its vascularized tissues to treat the infected plug. This is another example where a multidisciplinary approach can yield rewarding results in cases such as these.
Assuntos
Procedimentos Cirúrgicos Cardíacos/métodos , Remoção de Dispositivo/métodos , Insuficiência Cardíaca/etiologia , Ventrículos do Coração/cirurgia , Coração Auxiliar/efeitos adversos , Miocardite/microbiologia , Miocardite/cirurgia , Infecções Relacionadas à Prótese/etiologia , Infecções Relacionadas à Prótese/cirurgia , Choque Cardiogênico/etiologia , Titânio/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Miocardite/etiologia , Desenho de Prótese , Recuperação de Função Fisiológica , Retalhos Cirúrgicos , Resultado do TratamentoRESUMO
Described herein are 3 adults in whom histologic study of the left ventricular myocardium excised ("LV core") to insert a left ventricular assist device (LVAD) disclosed severe acute myocarditis and the inflammatory cells included numerous eosinophils (eosinophilic myocarditis). Examination of the clinical records disclosed elevated absolute eosinophil counts at the time of insertion of the LVAD and the counts rapidly (<30 days) returned to normal after the operation. Because of the numerous medications that each patient was taking at the time of LVAD insertion, identification of a specific initiating medication as its cause was not possible. Of the 3 patients, 2 had idiopathic-dilated cardiomyopathy and 1 had ischemic cardiomyopathy and each had had heart failure for years. The eosinophilic myocarditis in these 3 patients appears to have been transient and superimposed on the earlier cardiomyopathy.
Assuntos
Procedimentos Cirúrgicos Cardíacos/métodos , Eosinofilia/diagnóstico , Insuficiência Cardíaca/cirurgia , Ventrículos do Coração/patologia , Coração Auxiliar , Miocardite/diagnóstico , Miocárdio/patologia , Idoso , Biópsia , Eletrocardiografia , Eosinofilia/complicações , Eosinofilia/cirurgia , Eosinófilos/patologia , Feminino , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/diagnóstico , Ventrículos do Coração/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Miocardite/complicações , Miocardite/cirurgia , Índice de Gravidade de DoençaRESUMO
Fulminant myocarditis (FM) is a rare, distinct form of myocarditis that has been difficult to classify. Since 1991, the definition of FM has evolved, and it is currently considered an acute illness with hemodynamic derangement and arrhythmias due to a severe inflammatory process requiring support of cardiac pump function and/or urgent management of serious arrhythmias. Diagnosis is aided through use of biomarkers and cardiac imaging, but endocardial biopsy remains the gold standard. Recent evidence has revealed that patients with FM are significantly more likely to die or require heart transplantation than those with the nonfulminant form, refuting previous studies proposing a paradoxically low mortality in patients with FM. Acute hemodynamic derangement is managed by intensive contemporary pharmacologic and interventional approaches, whereas the role of immunosuppressive therapy has not been clarified. Early recognition and aggressive management are essential for favorable outcomes. In conclusion, FM is an inflammatory process requiring intensive support, and it causes a higher morbidity and mortality than acute nonfulminant myocarditis.
Assuntos
Estado Terminal/mortalidade , Transplante de Coração/métodos , Imagem Cinética por Ressonância Magnética/métodos , Miocardite/diagnóstico , Miocardite/epidemiologia , Biomarcadores/sangue , Biópsia por Agulha , Estado Terminal/terapia , Feminino , Hemodinâmica/fisiologia , Humanos , Imuno-Histoquímica , Incidência , Masculino , Miocardite/patologia , Miocardite/cirurgia , Doenças Raras , Medição de Risco , Resultado do TratamentoRESUMO
Ischemic heart disease is a growing worldwide epidemic. Improvements in medical and surgical therapies have reduced early mortality after acute myocardial infarction and increased the number of patients living with chronic heart failure. The irreversible loss of functional cardiomyocytes puts these patients at significant risk of ongoing morbidity and mortality after their index event. Recent evidence suggests that inflammation is a key mediator of postinfarction adverse remodeling in the heart. In this review, we discuss the cardioprotective and deleterious effects of inflammation and its mediators during acute myocardial infarction. We also explore the role of mesenchymal stem cell therapy to limit secondary injury and promote myocardial healing after myocardial infarction.
Assuntos
Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/imunologia , Infarto do Miocárdio/cirurgia , Miocardite/cirurgia , Miócitos Cardíacos/imunologia , Regeneração , Animais , Humanos , Células-Tronco Mesenquimais/metabolismo , Infarto do Miocárdio/imunologia , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/patologia , Miocardite/imunologia , Miocardite/metabolismo , Miocardite/patologia , Miócitos Cardíacos/metabolismo , Miócitos Cardíacos/patologia , Recuperação de Função Fisiológica , CicatrizaçãoRESUMO
: Heart transplantation is a life-saving therapy for some patients admitted for acute myocarditis. However, controversial exists about the major risk of rejection following heart transplantation in specific types of myocarditis. Because of relatively few data on the post heart transplant outcomes, we report the long-term follow-up of a 39-year-old patient with a previous history of ulcerative colitis, which rapidly worsened heart failure until an emergency heart transplant in 2004.The clinical course was complicated by many episodes of rejection; lastly, after the development of severe cardiac allograft vasculopathy, re-heart transplantation was needed. The main findings of this case are: 1) inflammatory aetiology should always be suspected in patients with concomitant autoimmune disease that developing rapidly progressing heart failure; 2) patients with inflammatory myocardial disease undergoing heart transplantation should also undergo strict immunological surveillance; 3) the option of performing the re-heart transplant in a patient with a so complex management in the first one could be uncertain, but in this case the young age and lack of noncardiac comorbidities were effective to favour the survivor after two immunologically so challenging heart transplantation.
Assuntos
Autoimunidade , Colite Ulcerativa/imunologia , Rejeição de Enxerto/imunologia , Transplante de Coração/efeitos adversos , Miocardite/cirurgia , Sarcoidose/cirurgia , Adulto , Biópsia , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/terapia , Angiografia Coronária , Diagnóstico Diferencial , Ecocardiografia , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/terapia , Humanos , Imunossupressores/administração & dosagem , Masculino , Miocardite/diagnóstico , Miocardite/imunologia , Plasmaferese , Valor Preditivo dos Testes , Reoperação , Sarcoidose/diagnóstico , Sarcoidose/imunologia , Choque Cardiogênico/imunologia , Fatores de Tempo , Resultado do TratamentoRESUMO
Giant cell myocarditis is a rare and highly lethal disorder with resultant cardiac insufficiency. It necessitates aggressive immune suppression therapy, although the results are often fatal. When it affects only the atria, the characteristics of the disease changes completely. In this case report, we present atypical presentation of atrial giant cell myocarditis with mass lesion, which completely resolved after successful surgical resection without immuno suppression therapy.
Assuntos
Células Gigantes/patologia , Neoplasias Cardíacas/patologia , Miocardite/patologia , Miocardite/cirurgia , Diagnóstico Diferencial , Átrios do Coração/patologia , Neoplasias Cardíacas/diagnóstico , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Miocardite/diagnóstico , Resultado do TratamentoRESUMO
Abstract Giant cell myocarditis is a rare and highly lethal disorder with resultant cardiac insufficiency. It necessitates aggressive immune suppression therapy, although the results are often fatal. When it affects only the atria, the characteristics of the disease changes completely. In this case report, we present atypical presentation of atrial giant cell myocarditis with mass lesion, which completely resolved after successful surgical resection without immuno suppression therapy.